A5049330053- Epigenetics and DNA Methylation
- Respiratory Support and Mechanisms
- Biochemical and Molecular Research
- Intensive Care Unit Cognitive Disorders
- Single-cell and spatial transcriptomics
- Bioinformatics and Genomic Networks
- melanin and skin pigmentation
- Neurogenesis and neuroplasticity mechanisms
- Histone Deacetylase Inhibitors Research
- Pneumothorax, Barotrauma, Emphysema
- Gut microbiota and health
- Autophagy in Disease and Therapy
- Computational Drug Discovery Methods
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Airway Management and Intubation Techniques
- Genomics and Chromatin Dynamics
- Cancer-related gene regulation
- Non-Invasive Vital Sign Monitoring
- COVID-19 Clinical Research Studies
- CRISPR and Genetic Engineering
- Helicobacter pylori-related gastroenterology studies
- Pharmacogenetics and Drug Metabolism
- Cardiac Arrest and Resuscitation
- Congenital heart defects research
Monash University
2021-2025
The Alfred Hospital
2025
Australian Regenerative Medicine Institute
2021-2024
Australian and New Zealand Intensive Care Society
2023-2024
Abstract Cellular heterogeneity in cancer is linked to disease progression and therapy response, although mechanisms regulating distinct cellular states within tumors are not well understood. We identified melanin pigment content as a major source of melanoma compared RNAseq data from high-pigmented (HPCs) low-pigmented cells (LPCs), suggesting EZH2 master regulator these states. protein was found be upregulated LPCs inversely correlated with deposition pigmented patient melanomas....
To describe and compare the demographics, management, outcomes for patients with COVID-19 admitted to intensive care units (ICUs) in Australia across various waves of COVID pandemic. People aged ≥16 years who were a participating ICU confirmed Short Period Incidence Study Severe Acute Respiratory Infection (SPRINT-SARI) study between February 2020 May 2024. Primary outcome: In-hospital mortality. Secondary outcomes: mortality; hospital lengths stay; supportive disease-specific therapies....
This study aims to identify biomarkers of intestinal repair and provide potential therapeutic clues for improving functional recovery prognostic performance after inflammation or injury. Here, we conducted a large-scale screening multiple transcriptomic scRNA-seq datasets patients with inflammatory bowel disease (IBD), identified 10 marker genes that potentially contribute barrier repairing: AQP8, SULT1A1, HSD17B2, PADI2, SLC26A2, SELENBP1, FAM162A, TNNC2, ACADS, TST. Analysis published...
Prone positioning may improve oxygenation in acute hypoxemic respiratory failure and was widely adopted COVID-19 patients. However, the magnitude timing of its peak effect remain uncertain with optimum dosage unknown. Therefore, we aimed to investigate prone on PaO
Abstract Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with to identify new treatments patients advanced cancer. Methods Tumours were sequenced the Illumina TruSight Oncology 500 (TSO‐500) platform or FoundationOne CDx panel. Mutations screened by two medical oncologists and pathogenic mutations categorised referencing literature. Variants unknown significance...
Abstract The biological and molecular mechanisms that underpin the malignant transformation of normal melanocytes to melanomas are largely unknown. In part, this is due limited understanding human melanocyte homeostasis how respond oncogenic insults such as ultraviolet radiation (UVR). This particularly true for interfollicular epidermal melanocytes, which have highest levels UVR exposure from whence most thought arise. These knowledge gaps impede development strategies active, targeted...
Neural tube closure in vertebrates is achieved through a highly dynamic and coordinated series of morphogenic events involving neuroepithelium, surface ectoderm, neural plate border. Failure this process the caudal region causes spina bifida. Grainyhead-like 3 (GRHL3) an indispensable transcription factor for as constitutive inactivation Grhl3 gene mice leads to fully penetrant Here, single-cell transcriptomics we show that at E8.5, time-point preceding mouse closure, co-expression Grhl3,...
Neural tube closure in vertebrates is achieved through a highly dynamic and coordinated series of morphogenic events involving neuroepithelium, surface ectoderm, neural plate border. Failure this process the caudal region causes spina bifida. Grainyhead-like 3 (GRHL3) an indispensable transcription factor for as constitutive inactivation Grhl3 gene mice leads to fully penetrant Here, single-cell transcriptomics we show that at E8.5, time-point preceding mouse closure, co-expression Grhl3,...
ABSTRACT Cellular heterogeneity in cancer is linked to disease progression and therapy response, although the mechanisms regulating distinct cellular states within tumours are not well understood. To address this, we identified melanin pigment content as a major source of phenotypic functional melanoma compared RNAseq data from high (HPC) low pigmented cells (LPC), revealing polycomb repressor complex protein, EZH2, master regulator these states. EZH2 but RNA expression, was found be...
ABSTRACT The enhancer of zeste homolog 2 (EZH2) oncoprotein is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here, we...
ABSTRACT Functional variation between cancer cells (intra-tumoral heterogeneity) poses a major challenge to treating and managing patients. Melanomas are typically composed of with heterogeneous content melanin pigment. Pigment production is hallmark normal melanocytic differentiation, however the functional consequences in melanoma remains poorly understood owing lack experimental approaches for detection pigment unfixed cells. Here, we describe novel flow cytometric method high purity...
Abstract PURPOSE Systematic repurposing of approved medicine for another indication represents an attractive strategy to accelerating drug development in oncology. Herein we present a combining biomarker testing with identify new treatments patients advanced cancer. METHODS Tumours were sequenced Illumina TruSight Oncology 500 (TSO-500) platform or the FoundationOne® CDx panel. Mutations manually screened by two medical oncology clinicians and pathogenic mutations categorised reference...
The enhancer of zeste homolog 2 (EZH2) oncoprotein is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here, we...
9562 Background: Despite revolutionary advances in systemic therapies for melanoma, many patients with metastatic disease have limited treatment options and some sites of remain particularly challenging to control, such as brain liver metastases. We sought define anatomical site-specific mutational profiles melanoma metastases from which potentially novel personalized therapeutic opportunities may be developed. Methods: Targeted exome genomic profiling was performed via the FoundationOneCDx...
Background : Patients with intestinal barrier injury have severe infection complications and higher mortality. Our study aims to identify novel biomarkers therapeutic targets for mucosa repair.Methods We used multiple samples datasets combined single-cell sequencing screen out the key genes that may contribute mucosal healing first time conducted preliminary exploration verification using external mouse embryonic intestines. A pilot observational in patients prophylactic ileostomy was...
Abstract The enhancer of zeste homolog 2 (EZH2) oncogene is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are also described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here,...